CHICAGO, Aug. 30 /PRNewswire-FirstCall/ -- Advanced
Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS),
a biopharmaceutical company engaged in the discovery, development
and commercialization of novel drugs in the therapeutic areas of
infection, oncology and respiratory diseases, today announced the
publication of a research paper in the journal Bioorganic and
Medicinal Chemistry Letters that reports data using the
Company's core triterpenoid platform technology in the discovery
and development of new cancer therapeutic agents.
(Logo:
http://photos.prnewswire.com/prnh/20080218/ALSLOGO)
(Logo:
http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)
Scientists at Advanced Life Sciences have identified a novel
class of proprietary triterpenoids that cause cell death
predominantly via the induction of apoptosis, which is a highly
regulated process by which excessive or harmful cells are
eliminated in order to maintain normal cell development and tissue
homeostasis. Defects in the apoptotic cellular machinery and
apoptosis inducing pathways often result in uncontrolled cell
proliferation, tumor development and other malignant diseases.
Resistance to apoptosis contributes greatly to the failure of
cancer prevention and treatment. Thus, the triterpenoids
discovered in this study may lead to important new therapeutic
agents in the treatment of cancer. The article published
online ahead of print can be found at
http://dx.doi.org/10.1016/j.bmcl.2010.07.120
"Today's scientific publication demonstrating the potential of
triterpenoids as potent anticancer agents, as well as the results
we have generated showing the anti-infective activity of
triterpenoids against a variety of viral and bacterial pathogens,
underscore the therapeutic and commercial potential of this novel
class of compounds and the productivity of our internal research
and development capability," said Dr. Michael T. Flavin, chief executive officer of
Advanced Life Sciences. "We look forward to advancing selected
compounds into preclinical development and to sharing these results
with potential corporate partners."
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in
the discovery, development and commercialization of novel drugs in
the therapeutic areas of infection, cancer and respiratory
diseases. The Company's lead candidate, Restanza, is a novel
once-a-day oral antibiotic in late-stage development for the
treatment of respiratory tract infections including CABP and
biodefense pathogens including anthrax, plague and tularemia. In
addition, the Company's earlier-stage pipeline is being enhanced
through in-licensing activities, such as the recently announced
collaboration with the University of British
Columbia, and through an internal R&D program focused on
discovering new treatments for cancer and infectious disease.
For more information, please visit us on the web at
www.advancedlifesciences.com or follow us on twitter at
http://twitter.com/advancedlifesci.
Forward-Looking Statements
Any statements contained in this press release that relate to
future plans, events or performance are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements represent our
management's judgment regarding future events. The Company
does not undertake any obligations to update any forward-looking
statements whether as a result of new information, future events or
otherwise. Our actual results could differ materially from
those discussed herein due to several factors including the success
and timing of our clinical trials and our ability to obtain and
maintain regulatory approval and labeling of our product
candidates; our plans to develop and commercialize our product
candidates; the loss of key scientific or management personnel; the
size and growth of potential markets for our product candidates and
our ability to serve those markets; regulatory developments in the
U.S. and foreign countries; the rate and degree of market
acceptance of any future products; the accuracy of our estimates
regarding expenses, future revenues and capital requirements; our
ability to obtain financing on terms acceptable to us; our ability
to obtain and maintain intellectual property protection for our
product candidates; the successful development of our sales and
marketing capabilities; the success of competing drugs that become
available; and the performance of third party collaborators and
manufacturers. These and additional risks and uncertainties
are detailed in the Company's filings with the Securities and
Exchange Commission.
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright . 30 PR Newswire